New pill could shrink rare joint tumors without surgery

NCT ID NCT05059262

Ongoing Disease control Sponsor: Deciphera Pharmaceuticals, LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests vimseltinib, an oral drug, for tenosynovial giant cell tumor (TGCT) when surgery isn't possible. About 123 adults with symptomatic TGCT will receive either vimseltinib or a placebo for 24 weeks, then all can get the drug. The main goal is to see if the drug shrinks tumors on MRI scans.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: vimseltinib (a drug taken by mouth)
What this could lead to: If it works, this could offer a non-surgical treatment option for people with TGCT, shrinking tumors and easing symptoms.
What could go wrong: This is still an experimental drug. It may not shrink tumors enough, and side effects are possible. The trial is also relatively small (123 people).

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Giant Cell Tumor of Tendon Sheath tenosynovial giant cell tumor tenosynovial giant cell tumor, diffuse type tenosynovial giant cell tumor, localized type

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GIANT CELL TUMOR OF TENDON SHEATH PIGMENTED VILLONODULAR SYNOVITIS TENOSYNOVIAL GIANT CELL TUMOR TENOSYNOVIAL GIANT CELL TUMOR, DIFFUSE TENOSYNOVIAL GIANT CELL TUMOR, LOCALIZED

Contacts and locations

Locations

Cancer & Haematology Centre, The Churchill Hospital - Oxford University Hospitals NHS Foundation Trust

London, United Kingdom
Centre Léon Bérard

Lyon, France
Chris O'Brien Lifehouse

Camperdown, Australia
City of Hope

Duarte, California, 91010, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Duke Sarcoma Research

Durham, North Carolina, 27710, United States
Fondazione IRCCS Istituto Nazionale dei Tumori

Milan, Italy
Fundacion Jimenez Diaz

Madrid, Spain
Helios Klinikum Berlin-Buch

Berlin, Germany
Hospital Clinico San Carlos

Madrid, Spain
Hospital Universitario Vall d'Hebron

Barcelona, Spain
Hospital de la Santa Creu i Sant Pau

Barcelona, Spain
Institut Bergonié

Bordeaux, France
Institut Gustave Roussy

Villejuif, France
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

Naples, Italy
Istituto Nazionale Tumori Regina Elena

Rome, Italy
Istituto Oncologico Veneto

Padua, Italy
Istituto Ortopedico Rizzoli

Bologna, Italy
Klinika Nowotworów Tkanek Miękkich, Kości i Czerniaków Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy

Warsaw, Poland
Leiden University Medical Center

Leiden, Netherlands
Mayo Clinic Rochester

Rochester, Minnesota, 55902, United States
McGill University

Montreal, Canada
Memorial Sloan-Kettering Cancer Center

New York, New York, 10016, United States
Ohio State University

Columbus, Ohio, 43210, United States
Oslo University Hospital

Oslo, Norway
Prince of Wales Hospital

Hong Kong, Hong Kong
Princess Margaret Hospital

Toronto, Canada
Seattle Cancer Care Alliance

Seattle, Washington, 98109, United States
UC Davis Comprehensive Cancer Center

Sacramento, California, 95817, United States
University College London Hospitals

London, United Kingdom
University Hospital Essen (Universitätsklinikum Essen)

Essen, Germany
University of Colorado

Aurora, Colorado, 80045, United States
University of Kansas

Kansas City, Kansas, 66160, United States
University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States
Universitäts-Kinderspital beider Basel (UKBB)

Basel, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.